Pasithea Therapeutics Corp. (KTTAW) Accounts Payables (2020 - 2026)

Pasithea Therapeutics has disclosed Accounts Payables across 7 years of filings, most recently posting $1.8 million for Q2 2026.

• In Q2 2026, Accounts Payables rose 16.21% year-over-year to $1.8 million; the TTM figure through Jun 2026 stood at $1.8 million (up 16.21% YoY), while the FY2025 annual figure was $1.1 million, up 1.0% from the prior year.
• Accounts Payables came in at $1.8 million for Q2 2026 at Pasithea Therapeutics, up from $1.5 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $2.6 million in Q4 2023 to a low of $433684.0 in Q1 2022.
• Average Accounts Payables over 5 years is $1.5 million, with a median of $1.4 million recorded in 2023.
• Year-over-year, Accounts Payables soared 233.78% in 2023 and plunged 64.67% in 2024.
• Over 5 years, Accounts Payables stood at $1.5 million in 2022, then jumped by 72.29% to $2.6 million in 2023, then plunged by 56.12% to $1.1 million in 2024, then advanced by 1.0% to $1.1 million in 2025, then surged by 62.49% to $1.8 million in 2026.
• Per Business Quant data, the three most recent Accounts Payables figures were $1.8 million in Q2 2026, $1.5 million in Q1 2026, and $1.1 million in Q4 2025.